share_log

和铂医药-B(02142)接获Cullinan有关终止协议的终止通知 Harbour将重新取得HBM7008的全球权利

Hengrui Medicine-B (02142) has received a termination notice from Cullinan regarding the termination agreement. Harbour will regain the global rights of HBM7008.

Zhitong Finance ·  Aug 8 07:27

Hepalink Pharmaceutical Group Limited-B (02142) announced that the Company received the notice of termination of the agreement related to Cullinan's termination...

According to the announcement released by Hepalink Pharmaceutical Group Limited-B (02142), the Company has received a termination notice from Cullinan regarding the termination of the agreement, which will take effect on November 3, 2024. Harbour has no obligation to refund any amount received under the agreement before termination. Harbour will regain the global rights of HBM7008 and continue to explore other development and potential commercial opportunities.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment